Synthesis of 2-(2-(1-benzyl indol-3-yl)-2-oxoethyl amino)acetic acid (3a) and 2-(2-(1-benzoyl indol-3-yl)-2-oxoethyl amino)acetic acid (3b). General procedure. -A suspension of 2a or 2b
(0.001 mol) and glycine (0.07 g, 0.001 mol) in potassium carbonate (5 mL, 1.1 mol L -1 ) was heated at 50°C for 10 min and then at 100°C for 30 min. After cooling, the reaction mixture was neutralized with diluted hydrochloric acid (1:1). The precipitate that was formed was collected by filtration and recrystallized from aqueous dioxane.
Synthesis of 1-[(1-benzyl indol-3-yl) carbomethyl]-2-thioxoimidazolidine-4-one (4a) and 1-[(1--benzoyl indol-3-yl) carbomethyl]-2-thioxoimidazolidine-4-one (4b).
General procedure. -A suspension of 3a or 3b (0.012 mol), acetic anhydride (6.3 g, 0.067 mol), anhydrous pyridine (15 mL) and ammonium thiocyanate (1.2 g, 0.015 mol) was heated at 110°C for 1 h. The volatiles were removed in vacuo and the residue was suspended in water (100 mL) and stirred for 1 h. The solid formed was collected by filtration and recrystallized from benzene-petroleum ether (60-80°C).
Synthesis of 1-[(1-benzyl indol-3-yl) carbomethyl]imidazolidine-2,4-dione (5a) and 1-[(1-benzoyl indol-3-yl) carbomethyl]imidazolidine-2,4-dione (5b).
General procedure. -A suspension of 4a or 4b (0.0055 mol), chloroacetic acid (10 g, 0.1 mol) and water (3 mL) was heated at 120°C for 12 h on a sand bath. The reaction mixture was then diluted with water (50 mL) and set aside in refrigerator at 0°C. The solid formed was collected by filtration and recrystallized from benzene-petroleum ether (60-80°C).
Synthesis of 5-(4-fluorobenzylidine)-1-(1-benzyl indol-3-yl)-2-thioxoimidazolidine-4-one (6a), 5--(4-fluorobenzylidine)-1-(1-benzoyl indol-3-yl)-2-thioxo-imidazolidine-4-one (6b), 5-(4-fluorobenzylidine)-1-(1-benzyl indol-3-yl)imidazolidine-2,4-dione (7a) and 5-(4-fluorobenzylidine)-1-(1--benzoyl indol-3-yl)imidazolidine-2,4-dione (7b)
. General procedure. -To a solution of 4a,b or 5a,b (0.001 mol) in absolute ethanol (10 mL) containing 3 drops of triethylamine, p-fluoro-benzaldehyde (0.11 g, 0.001 mol) was added. The reaction mixture was refluxed for 3 h. After evaporation of all solvent under vacuo, the residue was suspended in water (20 mL) and the solid formed was collected by filtration and recrystallized from aqueous ethanol to give 6a,b and 7a,b, respectively.
Synthesis of 5-amino-7-(
-A mixture of 4a,b or 5a,b (0.0005 mol) and p-fluorobenzylidene malononitrile (0.086 g, 0.0005 mol) in absolute ethanol (10 mL) containing triethylamine (0.5 mL) was refluxed for 2 h. The solid that formed was collected by filtration and recrystallized from dioxane.
Method B. -A mixture of 6a,b or 7a,b (0.001 mol) and malononitrile (0.066 g, 0.001 mol) in absolute ethanol (10 mL) containing triethylamine (0.5 mL) was refluxed for 3 h. The solid that formed was collected by filtration and recrystallized from dioxane.
Synthesis of 3-(1-benzyl indol-3-yl)quinoxalin-2(1H)one (11a) and 3-(1-benzoyl indol-3-yl)quinoxalin-2(1H)one (11b)
. General procedure. -To a solution of o-phenylenediamine (1.1 g, 0.01 mol) in absolute ethanol (20 mL) 10a or 10b (0.01 mol) was added. The reaction mixture was refluxed on a water bath for 1 h. The solvent was then evaporated to dryness under vacuo and the resulting residue was triturated with water (30 mL). The solid formed was collected by filtration, air-dried and recrystallized from chloroform. 
Synthesis of 2-chloro-3-(1-benzyl indol-3-yl)quinoxaline (12a) and 2-chloro-3-(1-benzoyl indol--3-yl)quinoxaline (12b).
General procedure. -A solution of 11a or 11b (0.01 mol) in phosphorus oxychloride (20 mL) was heated on a sand bath at 130°C for 1 h. After cooling, the reaction mixture was poured onto ice-water under stirring and the solid that formed was collected by filtration, air-dried and recrystallized from chloroform. -1-yl)-3-(1-benzyl indol-3-yl)quinoxaline (13a), 2-(piperidin-1-yl)--3-(1-benzoyl indol-3-yl)quinoxaline (13b), 2-morpholino-3-(1-benzyl indol-3-yl)quinoxaline  (14a), 2-morpholino-3-(1-benzoyl indol-3-yl)quinoxaline (14b), 2-(4-methylpiperazin-1-yl)-3-(1--benzyl indol-3-yl)quinoxaline (15a) and 2-(4-methylpiperazin-1-yl)-3-(1-benzoyl indol-3-yl) quinoxaline (15b). General procedure. -Compound 12a or 12b (0.01 mol) was fused with an appropriate aliphatic cyclic amine (0.01 mol) at 150°C on a sand bath for 3 h. After cooling and addition of water (20 mL), the solid formed was collected by filtration, air-dried and recrystallized from chloroform.
Synthesis of 2-(piperidin

Synthesis of 1-(2-(1-benzyl indol-3-yl)quioxalin-3-yl)hydrazine (16a) and 1-(2-(1-benzoyl indol-3-yl)quioxalin-3-yl)hydrazine (16b)
. General procedure. -To a solution of 12a or 12b (0.01 mol) in absolute ethanol (50 mL), hydrazine hydrate (2.5 mL, 99 %, 0.05 mol) was added and the reaction mixture was refluxed for 3 h. The solid that formed after cooling in refrigerator was collected by filtration and recrystallized from ethanol.
Synthesis of 2-azido-3-(1-benzyl indol-3-yl)quinoxaline (17a) and 2-azido-3-(1-benzoyl indol-3-yl)quinoxaline (17b).
General procedure. -A cold solution (0-5°C) of sodium nitrite (1 g, 0.144 mol) in water (15 mL) was added gradually within 15 min to a cold solution of 16a or 16b (0.01 mol) in concentrated hydrochloric acid (5 mL). After addition, the reaction mixture was set aside at room temperature for 1 h. The solid that formed was collected by filtration, air dried and recrystallized from chloroform. (4,3-a) quinoxaline (19b) . General procedure. -Compound 16a or 16b (0.01 mol) was treated with formic acid (25 mL) or acetic acid (25 mL) and allowed to stand at room temperature for 24 h and then refluxed for 4 h. After cooling, the reaction mixture was poured onto crushed ice and the suspension formed was filtered off, air-dried and recrystallized from chloroform.
Synthesis of 4-(1-benzyl indol-3-yl)-(1,2,4)-triazolo(4,3-a)quinoxaline (18a), 4-(1-benzoyl indol-3-yl)-(1,2,4)-triazolo(4,3-a)quinoxaline (18b), 1-methyl-4-(1-benzyl indol-3-yl)-(1,2,4)-triazolo(4,3-a)quinoxaline (19a) and 1-methyl-4-(1-benzoyl indol-3-yl)-(1,2,4)-triazolo
Biological assays
Antimicrobial evaluation. -Antimicrobial activity of the synthesized compounds was determined in vitro using the disc diffusion method (12) against pathogenic microorganisms: Escherichia coli, Pseudomonas aeruginosa (Gram-negative bacteria), Staphylococcus aureus, Bacillus cereus (Gram-positive bacteria) and one strain of fungi (Candida albicans). They were isolated from clinical samples and identified to the species level according to API 20E system (Analytab Products, Inc., USA) (bioMerieux, Australia). Antimicrobial activities of the tested compounds were estimated by placing presterilized filter paper discs (6 mm in diameter) impregnated with 25, 50 and 100 mg per disc in nutrient and MacConky agar media for bacteria and on Sabouraud dextrose agar for fungus. Dimethyl formamide (DMF) which showed no inhibition zone was used as a solvent for impregnation. The inhibition zones (IZ) of the tested compounds were measured after 24-48 h incubation at 37°C for bacteria and after 5 days incubation at 28°C for fungi. Cefotaxime (Hoechst-Roussel Pharmaceuticals, Germany, 30 mg per disc) and piperacillin (Bristol-Myers Squibb, Egypt, 100 mg per disc) were used as reference drugs for bacteria, while nystatin (Bristol-Myers Squibb, Egypt, 1.2 mg per disc) was used as reference drug for fungi.
Anti-cancer evaluation. In vitro studies. -Human ovarian cancer cell lines (OVCAR3 and BG-1) were obtained from the American Type Culture Collection, Rockville, USA). OVCAR3 cells were propagated in sterile growth medium RPMI-1640 * (Sigma-Aldrich, Germany) supplemented with 10 % fetal calf serum (Life Technologies, USA) and 1 % antibiotic mixture penicillin G sodium and streptomycin sulphate, Gibco Germany). BG-1 cells were propagated in DMEM/F-12 ** medium supplemented with 10 % fetal calf serum. Cells were incubated at 5 % CO 2 and at 37°C.
Cytotoxicity test (MTT).
-Cytotoxicity of the synthesized compounds was determined using the MTT [3-(4,5-dimethylthiazoyl-2-yl)2,5-diphenyltetrazolium bromide] assay according to Mosmann (13) . Subconfluent cells (logarithmically growing cells) were trypsinized and collected.
Cells were seeded in 96-well micro-plates (3´10 3 cells per well) in 100 mL RPMI--1640 culture medium and incubated at 37°C and 5 % CO 2 overnight. After overnight incubation, the cells were treated with the synthesized compounds dissolved in 10 mL DMSO per well and then incubated for further 24 hours. The medium was discarded and the cells were washed with sterile PBS; then 100 mL of the MTT (0.5 mg mL -1 ) solution were added to each well and cells were incubated for 4 h. The developed purple crystals were dissolved in 100 mL DMSO and absorbance was measured at 570 nm (ELISA reader, Biorad, USA).
Growth suppression of ovarian cancer xenografts in nude mice.
In vivo studies. -Female Swiss albino mice weighing 25-30 g obtained from Harlan Sprague Dawley, (USA) were housed at a constant temperature (24 ± 2°C) with alternating 12 h light and dark cycles and fed standard laboratory food and water ad libitum. Statistical analysis was preformed using the SPSS version 11.0. Data were expressed as percent of control of mean ± SD by one-way analysis of variance (ANOVA) followed by the LSD-test. All procedures involving animals were carried out in accordance with the guidelines for the care and use of laboratory animals and were approved by the Ethics Committee of the National Research Centre Cairo, Egypt. For inoculation into nude mice, OVCAR3 cells were washed with PBS, trypsinzed, resuspended in RPMI-1640 containing fetal calf serum, and pooled. After centrifugation, cells were resuspended in matrigel (BD Biosciences Discovery Labware, USA)-RPMI-1640 (1:1) at a concentration of 5´10 6 cells per 0.1 mL of matrigel. The mixture (0.1 mL) was injected subcutaneously into female athymic nude mice on the dorsal surface. Treatment began when the tumor reached a volume of 150 mm 3 on average, which took~4 weeks. Mice were randomized and treated orally by the tested compounds daily. Tumor volumes and body masses were monitored every 5 days over the course of treatment. Mice were sacrificed after 30 days of treatment (14) . 
RESULTS AND DISCUSSION
Chemistry
A similar method as that described by Bodendorf and Walk (15) for the preparation of 3-bromoacetyl indole was used to prepare the new starting compounds, 1-benzyl-(2a) and 1-benzoyl-3-bromoacetyl (2b) indoles. Mass spectra of 2a and 2b showed molecular ion peaks at m/z % = 327/329 (M + /M + +2, 12/10) and 341/343 (M + /M + +2, 7/5), respectively (Table II) .
Reaction of 2a,b with glycine in the presence of saturated potassium carbonate solution led to the formation of 2-(2-(1-benzyl indol-3yl)-2-oxoethyl amino)acetic acid (3a) and 2-(2-(1-benzoyl indol-3yl)-2-oxoethyl amino)acetic acid (3b) (Scheme 1). Heterocyclization of the latter compounds via their reactions with ammonium thiocyanate in acetic anhydride and in the presence of anhydrous pyridine using the method of Okuda et al. (16) gave 2-thioxoimidazolidine-4-one derivatives (4a,b) (Scheme 1). IR spectra of 4a,b showed absorption bands at 1240 cm -1 for C-S besides the carboxamide group peaks at 1675 and 1686 cm -1 . In addition, 1 H NMR spectrum of 4a revealed singlet signals at 4.01 and 4.12 ppm for CH 2 of the imidazolyl and carbomethyl groups, respectively, besides CH 2 of benzyl at 5.61 ppm (Table II) .
Acid hydrolysis of compounds 4a,b using aqueous monochloroacetic acid yielded the corresponding imidazolidine-2,4-dione derivatives (5a,b) (Scheme 1). IR spectra of 5a,b showed no absorption bands for C=S but showed an absorption band at 1705-1715 cm -1 for (C=O) groups.
Base catalyzed reaction of 4a,b and 5a,b with p-fluorobenzaldehyde led to the formation of the corresponding arylidene derivatives 6a,b and 7a,b, respectively (Scheme 1). Similarly to Mandour and Kassem's procedure (17) , condensation of the latter compounds with malononitrile under reflux and in the presence of a base led to the formation of condensed systems of pyrano(2,3-d)imidazole derivatives 8a,b and 9a,b, respectively (Scheme 1). The latter compounds could also be obtained by the condensation of 4a,b and 5a,b with p-fluorobenzylidene malononitrile in the presence of a base (Scheme 1). The products obtained by the two methods are identical in all aspects and were compared by TLC and melting points, which showed no differences. IR spectra of compounds 8a,b and 9a,b showed characteristic absorption bands at 2220-2223 cm -1 for CN and at 3220-3330 cm -1 for NH 2 . The 1 H NMR spectra of 8a,b and 9a,b showed the absence of CH=C protons of the parent compounds 6a,b and 7a,b but revealed singlet signals, 2H, of NH 2 at 5.76, 5.80, 5.90 and 6.1 ppm, respectively, besides other signals which showed similar shifts to that of the protons of the starting compounds (Table II) .
Oxidation of compounds 2a,b with selenium dioxide in absolute methanol under reflux afforded methyl 2-(1-benzyl indol-3-yl)-2-oxoacetate (10a) and methyl 2-(1-benzoyl indol-3-yl)-2-oxoacetate (10b) (18, 19) (Scheme 2). Heterocyclization of compounds 10a,b was afforded by their reactions with o-phenylenediamine to give quinoxaline-2(1H)-one derivatives 11a,b; compound 11a was previously reported (20) .
Compounds 11a,b, upon heating with excess of phosphorus oxychloride, afforded the corresponding 2-chloroquinoxaline derivatives 12a,b (Scheme 2). Reactivity of compounds 12a and 12b as chlorocompounds was tested via their reactions with different secondary amines, namely piperidine, morpholine and N-methylpiperazine and gave 2-substituted quinoxaline derivatives 13a,b-15a,b, respectively (Scheme 2). Reaction of 12a,b with hydrazine hydrate in refluxed ethanol yielded the corresponding hydrazino derivatives 16a,b (Scheme 2). Diazotization of 16a,b using sodium nitrite and concentrated hydrochloric acid led to the formation of the azido derivatives 17a and 17b (Scheme 2).
On the other hand, the resulting hydrazine compounds 16a,b were further converted to 1,2,4-triazolo(3,4-a)quinoxaline derivatives 18a,b and 19a,b upon refluxing in formic acid and acetic acid, respectively (Scheme 2). Structures of the new compounds were confirmed on the basis of elemental analyses (Table I) as well as spectral data, IR, 1 H NMR, and MS (Table II) .
Antimicrobial activity
All the synthesized compounds were tested for their antimicrobial activity against pathogenic microorganisms E. coli, P. aeruginosa (Gram-negative bacteria), S. aureus, B. cereus (Gram-positive bacteria) and one strain of fungi (C. albicans) at concentrations of 0.88, 0.44 and 0.22 mg mm -2 (Table III) . Compounds 15a,b were the most active of all the tested compounds, with inhibition zones bigger or comparable to that obtained by reference drugs against P. aeruginosa, S. aureus and B. cereus; the same applies to 11a,b against E. coli and P. aeruginosa. On the other hand, compounds 12a and 12b were found to be most active of all the tested compounds with inhibition zone of 32 mm against C. albicans compared to the reference drug nystatin (40 mm) at 1.2 mg per disc. The rest of the tested compounds were non-active against all microorganisms.
Anticancer activity
All the synthesized compounds were initially screened for in vitro anticancer activity at a concentration of 10 -7 mol L -1 against two human cancer cell lines, OVCAR3 and BG-1, compared to vitamin D [1,25(OH) 2 D 3 ] (10 -7 mol L -1 ) using the MTT assay (13) . The growth inhibition action of the tested compounds was reported after 24 and 48 h for each cell line (Table IV) . Compounds 18a, 12a and 12b were found to be the most cytotoxic, with growth inhibition of 98.5 ± 1.2, 97 ± 0.6 and 96.14 ± 0.5 %, respectively, after treatment for 24 h and 99.9 ± 1.5, 98.6 ± 0.6 and 97.6 ± 0.6, respectively, after treatment for 48 h compared to vitamin D (43.9 ± 7.8 and 59.8 ± 5.3 %) against OVCAR3. Also, compounds 18a, 12a and 12b were most cytotoxic against BG-1, with inhibition growth of 98.9 ± 1.1, 98.0 ± 0.8 and 97.7 ± 0.7 %, respectively, after treatment for 24 h and 99.8 ± 1.3, 98.9 ± 0.8 and 98.0 ± 0.5 %, respectively, after treatment for 48 h compared to vitamin D (62.4 ± 17.7 and 71.1 ± 14.2 %), respectively.
The most cytotoxic of all the tested compounds (4a,b, 5a,b, 12a,b, 13a,b, 14a, 15a,  17a, 18a,b and 19a,b) were next evaluated for in vivo growth suppression of ovarian cancer xenografts in nude mice. OVCAR3 cell was injected subcutaneously to a size of about 150 mm 3 . Subsequently, daily drug administration of 1 mmol per day per gram body mass was conducted for five days and mice were scarificed after 30 days of treatment (Table V) . Data expressed as percent of tumor growth suppression compared to control were calculated. 2-Chloro-3-(1-benzyl indol-3-yl) quinoxaline (12a) showed potent efficacy, with tu- mor growth suppression 100.0 ± 0.3 % after 25 days, whereas vitamin D showed tumor growth suppression of 98.6 ± 5.4 % after 25 days.
CONCLUSIONS
Described herein are the synthesis, antimicrobial and anticancer activities of some new 1-benzyl-and 1-benzoyl-3-heterocyclic indole derivatives. The results show that compounds 3-(1-substituted indol-3-yl)quinoxalin-2(1H)ones (11a,b) and 2-(4-methyl piperazin-1-yl)-3-(1-substituted indol-3-yl) quinoxalines (15a,b) were most active against P. aeruginosa, B. cereus and S. aureus, while 2-chloro-3-(1-substituted indol-3-yl)quinoxalines (12a,b) were most active against C. albicans. On the other hand, 2-chloro-3-(1-benzyl indol-3-yl) quinoxaline (12a) displays potent efficacy of ovarain cancer xenografts in nude mice with complete tumor growth suppression. Finally, this SAR study has indicated that the conjugated indole-quinoxaline is vital for the antimicrobial activity and potential anti-cancer efficacy. 
